Educational program for bladder cancer patients undergoing surgery
Official title: Comprehensive Geriatric Assessment Utilization for Bladder Cancer Patients Undergoing Radical Cystectomy: A Randomized Controlled Trial
Run by University of Chicago · NCT06427824 · Data updated 2026-11-12
This study is testing an educational program with videos for bladder cancer patients having surgery to see if it helps them manage side effects better, either on its own or with extra support from geriatric services.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 85 (estimated) |
| Sponsor | University of Chicago Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | August 9, 2024 |
| Main results expected | October 1, 2026 |
| Study ends | October 1, 2026 |
| Registry record updated | October 3, 2025 |
| Trial ID | NCT06427824 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 65 and older who are undergoing radical cystectomy for bladder cancer.
✕Probably not a fit
Patients undergoing radical cystectomy for non-cancerous reasons or for cancers other than bladder cancer will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study provides an educational program for individuals with bladder cancer who are scheduled to undergo radical cystectomy. Participants will watch videos that teach strategies to minimize negative side effects related to surgery, such as mobility issues and medication management. They will also complete questionnaires to assess the effectiveness of the educational content and their application of learned strategies. Participants will be randomly assigned to either receive the educational videos alone or in combination with geriatric services and follow-up visits after surgery.
Why it matters
Potential benefit: If successful, this program could significantly improve the quality of life and recovery outcomes for bladder cancer patients undergoing surgery.
How similar studies have gone: Other studies have shown success with educational interventions in surgical settings, indicating potential for positive outcomes in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Participants capable of giving consent * Participants undergoing radical cystectomy (both for curative and palliative intent) for bladder cancer diagnosed by tissue pathology with urinary diversion at the University of Chicago * Participants undergoing neoadjuvant chemotherapy will be included * Participants will be included regardless of gender, race or ethnicity * Participants greater than or equal to 65 years of age Exclusion Criteria * Radical cystectomy for non-oncologic indications * Palliative cystectomy for cancers other than bladder cancer (i.e. prostate, rectal, cervical)
Where it's running
-
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, United States Recruiting
Study contacts
- Principal investigator: Piyush Agarwal — University of Chicago
- Study coordinator: Piyush K Agarwal, MD
- Email: cancerclinicaltrials@bsd.uchicago.edu
- Phone: 773-702-3080
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy
This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.
-
Urinary Cell-Free DNA Test for Urothelial Cancer Origin
This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.
-
BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy
This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.
-
Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion
This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.
-
Personalized 3D Tumoroids from Your Tumor to Test Treatments
Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.